Skip to content

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03170375
Enrollment
71
Registered
2017-05-31
Start date
2019-01-02
Completion date
2025-01-23
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

obesity, sodium, DASH diet, hypertension, vascular stiffness, diastolic function

Brief summary

Tens of thousands of Veterans have heart failure with preserved ejection fraction (HFpEF), and suffer poor quality of life, frequent hospitalizations, and high death rates. Older Veterans and those with high blood pressure, obesity, and the metabolic syndrome (abnormal cholesterol and resistance to insulin's effects) are particularly at risk for HFpEF. However, it is not clear why only some Veterans in this risk group eventually develop HFpEF. Extensive information from experimental animal models and some human studies suggests that dietary patterns in vulnerable 'salt-sensitive' people could contribute to the risk for HFpEF. Reducing salt intake and increasing overall dietary quality in at-risk Veterans could prevent heart and blood vessel damage that ultimately leads to HFpEF. Reducing the development of HFpEF, which currently has no definitive treatment, is highly relevant to the VA's mission to emphasize prevention of disease and population health.

Detailed description

COVID-19 in-person visit hold has been removed- screening and actively enrolling. We are not currently performing sublingual darkfield microscopy because of the need for close face-to-face contact with an open-mouthed patient for several minutes in the setting of COVID-19 pandemic. Patients with heart failure (HF) account for over 1,200,000 VA outpatient visits per year, and HF remains the most common cause for hospital admission in the VA. Approximately 1/3 of Veterans with HF have 'preserved' ejection fraction (HFpEF), or relatively normal contractile function of the heart; such patients suffer functional decline and poor quality of life, and half die within 5 years after diagnosis. Risk factors for developing HFpEF are more common in Veterans than the general population, and the burden of HFpEF to the VA system will rise in the years ahead as these Veterans age. Preventive efforts are critical, but are hampered by gaps in knowledge related to HFpEF pathophysiology. The long term goal of this proposal is to prevent the onset of HFpEF in at-risk Veterans. Hypertension (HTN) confers the highest population-attributable risk for HFpEF, particularly when accompanied by the metabolic syndrome, a constellation of obesity, insulin resistance, and dyslipidemia. Animal models of HTN and metabolic syndrome develop HFpEF due to microvascular oxidative stress and inflammation induced by high sodium intake. Recent data from cardiac biopsies confirm similar mechanisms in human HFpEF. Dietary sodium restriction is widely recommended to prevent HTN-associated heart disease in humans, but this advice is now controversial. Few studies have examined how individual differences in response to sodium intake affect risk. Salt-sensitive persons have blood pressure (BP) that changes in parallel with sodium intake, and commonly develop cardiovascular abnormalities associated with HFpEF. The overall objective of this proposal is to evaluate salt-sensitivity as a novel, diet-responsive risk factor for incident HFpEF in Veterans with HTN and metabolic syndrome. The central hypothesis is that the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating pattern will improve cardiovascular functional and structural risk factors for HFpEF in Veterans with the salt-sensitive phenotype. Guided by findings in experimental models, cohort studies, and strong preliminary evidence from the investigators' research group, this hypothesis will be tested in a two-phase study and by pursuing three specific aims: 1) Determine effects of DASH/SRD on functional and structural cardiovascular HFpEF risk factors in salt-sensitive vs. salt-resistant Veterans, 2) measure the effect of an electronically-delivered tailored-messaging intervention on DASH/SRD adherence, and 3) determine effects of DASH/SRD intervention and adoption on microvascular function and assess the endothelial glycocalyx as a biomarker of cardiovascular response to DASH/SRD. Phase 1 of the study is a sequential comparison of DASH/SRD vs. control diet for two weeks each, and Phase 2 a 6-month extension to promote DASH/SRD adherence. The salt-sensitive phenotype will be defined by between-diet changes in 24-hour mean BP during Phase 1. In Phase 2, the efficacy of motivational interviewing-based counseling and the Women's and Men's Hypertension Experiences and Emerging Lifestyles Intervention (WHEELS-I), a tailored messaging program, to sustain DASH/SRD adherence, will be compared. Echocardiography and arterial tonometry will be used to assess HFpEF-related cardiovascular parameters during short- and longer-term dietary modification and their interaction with salt-sensitivity. In vivo microscopy and novel blood testing will assess microvascular function and the integrity of the endothelial glycocalyx, a blood vessel lining that is sodium-responsive and may mediate the adverse effects of salt-sensitivity. This proposal is innovative because it represents the first study to examine salt-sensitivity as a factor promoting HFpEF in Veterans with HTN and metabolic syndrome, the highest risk group for incident HFpEF. Moreover, it aims to link microvascular dysfunction, an important pathway in human HFpEF, with endothelial glycocalyx damage, a potential biomarker for sodium-mediated vascular risk. The proposed research is significant because it will vertically advance the investigators' understanding of how dietary factors contribute to the pathophysiology of HFpEF, a major and growing health threat to Veterans.

Interventions

BEHAVIORALPerformance of WHEELS-I in promoting DASH/SRD adoption

All participants will receive motivational interviewing (MI) based counseling. Participants in the MI + WHEELS-I arm will also receive the WHEELS-I electronically-delivered tailored messaging.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

Phase 1 of study: sequential design, 14 days each of usual diet followed by 14 days of sodium-restricted DASH diet Phase 2 of study: randomized assignment, 6 months of motivational interviewing vs. motivational interviewing plus mobile application-based promotion of dietary adherence

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Veterans aged 45 years with HTN * here defined as screening systolic BP 130 and/or diastolic BP 85 mmHg, or current use of anti-hypertensive drugs * and metabolic syndrome * body mass index 30 kg/m2 and/or waist circumference \>94 cm * Participants must also be willing to participate in the WHEELS-I program by using a smartphone application or email

Exclusion criteria

* On-treatment systolic BP of \>160 mmHg at screening visit * previous history of HF * left ventricular ejection fraction \<50% * moderate or severe valvular heart disease * myocardial infarction or stroke within the prior 6 months * chronic kidney disease with estimated glomerular filtration rate \<45 ml/min/ 1.73m2 * unoperated aortic aneurysm for which surgery is indicated, prior hyperkalemia requiring urgent treatment * hemoglobin \<9 gm/dL * investigator-determined factors: severe pulmonary disease, e.g.: * oxygen-requiring * hepatic disease, e.g.: * cirrhosis * severely uncontrolled diabetes (hemoglobin A1c \>10%) * active cancer other than non-melanoma skin or low-risk prostate cancer * other comorbidity with expected survival \<12 months * active alcohol/illicit substance abuse * and/or a history of persistent nonadherence to treatment * Veterans involved in another study (unless it is survey-only and the other investigator will allow us to invite the person in a survey-only study to consider our study)

Design outcomes

Primary

MeasureTime frameDescription
Carotid-femoral Pulse Wave VelocityPhase 1 of study, change between week 2 and week 4Phase 1 primary hypothesis: greater reduction in carotid-femoral pulse wave velocity with DASH diet in individuals with salt-sensitive blood pressure Change in velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Left Ventricular Mass IndexPhase 2 of study, change from baseline to 6 monthsLeft ventricular mass indexed to body surface area. Larger/greater left ventricular mass index is associated with increased long-term risk of cardiovascular events, including the development of heart failure. Normal values for men are 49-115 g/m² and for women 43-95 g/m²

Secondary

MeasureTime frameDescription
Global Longitudinal Left Ventricular StrainPhase 1 of study, change between week 2 to week 4Global longitudinal left ventricular strain (GLS), a sensitive measure of ventricular systolic function GLS is calculated by dividing the reduction in length of a myocardial (heart) segment from the end of diastole (maximum relaxation) to the end of systole (maximum contraction) by the segment's original length at end-diastole (i.e. change in length/original length). GLS is averaged across six myocardial segments, is expressed in a percentage, and is negative by convention since cardiac segment length decreases during systole. The more negative/greater magnitude, the better the GLS. Normal GLS is -18% to -22%. Low GLS is associated with long-term increased risk of cardiovascular events, including the development of heart failure.
Carotid-femoral Pulse Wave VelocityPhase 2 of study, change from baseline to 6 monthsVelocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness

Other

MeasureTime frameDescription
Clinic Systolic Blood PressurePhase 2 of study, change from baseline to 6 monthsChange in systolic blood pressure obtained in clinic with automated brachial cuff
Clinic Diastolic Blood PressurePhase 2 of study, change from baseline to 6 months
Salt-sensitivity PhenotypePhase 1 of study, change between week 2 and week 4Salt-sensitive blood pressure means that blood pressure changes more than 'normal' when dietary sodium intake changes, i.e. increases or decreases in parallel with sodium intake. Having a salt-sensitive blood pressure pattern is an independent long-term risk factor for cardiovascular events. Variable testing approaches, blood pressure thresholds, and methods of blood pressure measurement have been proposed in the literature to define blood pressure salt-sensitivity. In this study, we report salt-sensitive vs. non salt-sensitive as a binary variable. Change in 24-hour mean blood pressure of \>= 4 mmHg between the ad-lib and home-delivered meal periods of Phase 1 defines the salt-sensitive blood pressure phenotype
Urine Sodium and Potassium RatiosPhase 2 of study, change from baseline to 6 monthsUnitless ratio of urine sodium (in mmol) divided by urine potassium (in mmol), measured from spot samples taken from 24-hour urine samples.
TriglyceridesPhase 2 of study, change from baseline to 6 monthsSerum triglyceride changes during dietary intervention
24-hour Urinary Sodium ExcretionPhase 2 of study, change from baseline to 6 monthsMeasure of daily dietary sodium intake
Sodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ)Phase 2 of study, change from baseline to 6 monthsSodium-restricted DASH diet score on FFQ, measured by quintiles of intake in 8 dietary domains as compared with age- and sex-matched norms from NHANES national US survey data. Score ranges 8-40 points, with higher scores indicating greater adherence
Sodium-restricted DASH Diet AdherencePhase 2 of study, change from baseline to 6 monthsAnalysis of 3-day food diaries by a Registered Dietitian, utilizing the Nutrition Data System for Research. DASH diet adherence score based on proportion of recommended daily intake in 9 domains, score ranges 0-9 points with higher scores indicating greater adherence

Countries

United States

Participant flow

Pre-assignment details

Phase 1: Screening visit: Follow baseline diet for 2 weeks Excluded if patient couldn't wean from renin-angiotensin-aldosterone system (RAAS) inhibitors and diuretics without complications 2-week visit: follow DASH-SRD diet for 2 weeks 4-week visit: randomized into Arm 1 or 2 and begin phase II of study.

Participants by arm

ArmCount
Phase 1: 2-week Diet As Usual Then 2 Weeks of DASH/SRD Diet
This arm includes all participants who started Phase 1 of the study. Phase 1 took place prior to randomization into either the Motivational Interviewing or Motivational Interviewing + WHEELS-I arm.
71
Motivational Interviewing + WHEELS-I
In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I). Randomization will occur after phase 1 of the study which includes 2 weeks of an ad lib diet followed by 2 weeks of prepared pre-packaged DASH/SRD meals.
28
Motivational Interviewing
Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan. Randomization will occur after phase 1 of the study which includes 2 weeks of an ad lib diet followed by 2 weeks of prepared pre-packaged DASH/SRD meals.
38
Total137

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Phase 1 - 4 WeeksWithdrawal by Subject500
Phase 2 - 6 MonthsWithdrawal by Subject032

Baseline characteristics

CharacteristicTotalPhase 1: 2-week Diet As Usual Then 2 Weeks of DASH/SRD DietMotivational Interviewing + WHEELS-IMotivational Interviewing
Age, Continuous
Phase 1
66 years
STANDARD_DEVIATION 8
66 years
STANDARD_DEVIATION 8
Age, Continuous
Phase 2
66 years
STANDARD_DEVIATION 8
64 years
STANDARD_DEVIATION 9
67 years
STANDARD_DEVIATION 8
BMI
Phase 1
34.4 kg/m^2
STANDARD_DEVIATION 5.1
34.4 kg/m^2
STANDARD_DEVIATION 5.1
BMI
Phase 2
34.5 kg/m^2
STANDARD_DEVIATION 5.1
34.7 kg/m^2
STANDARD_DEVIATION 4.7
34.4 kg/m^2
STANDARD_DEVIATION 5.5
Diastolic Blood Pressure
Phase 1
72 mmHg
STANDARD_DEVIATION 11
72 mmHg
STANDARD_DEVIATION 11
Diastolic Blood Pressure
Phase 2
73 mmHg
STANDARD_DEVIATION 11
74 mmHg
STANDARD_DEVIATION 11
72 mmHg
STANDARD_DEVIATION 11
Ethnicity (NIH/OMB)
Phase 1
Hispanic or Latino
4 Participants4 Participants
Ethnicity (NIH/OMB)
Phase 1
Not Hispanic or Latino
63 Participants63 Participants
Ethnicity (NIH/OMB)
Phase 1
Unknown or Not Reported
4 Participants4 Participants
Ethnicity (NIH/OMB)
Phase 2
Hispanic or Latino
3 Participants3 Participants0 Participants
Ethnicity (NIH/OMB)
Phase 2
Not Hispanic or Latino
59 Participants23 Participants36 Participants
Ethnicity (NIH/OMB)
Phase 2
Unknown or Not Reported
4 Participants2 Participants2 Participants
HDL Cholesterol
Phase 1
45 mg/dL
STANDARD_DEVIATION 10
45 mg/dL
STANDARD_DEVIATION 10
HDL Cholesterol
Phase 2
45 mg/dL
STANDARD_DEVIATION 10
43 mg/dL
STANDARD_DEVIATION 9
46 mg/dL
STANDARD_DEVIATION 11
Hemoglobin A1c
Phase 1
6.2 %
STANDARD_DEVIATION 1.1
6.2 %
STANDARD_DEVIATION 1.1
Hemoglobin A1c
Phase 2
6.3 %
STANDARD_DEVIATION 1.1
6.3 %
STANDARD_DEVIATION 1
6.3 %
STANDARD_DEVIATION 1.1
Hip Circumference
Phase 1
117 cm
STANDARD_DEVIATION 15
117 cm
STANDARD_DEVIATION 15
Hip Circumference
Phase 2
117 cm
STANDARD_DEVIATION 15
118 cm
STANDARD_DEVIATION 11
116 cm
STANDARD_DEVIATION 17
Race (NIH/OMB)
Phase 1
American Indian or Alaska Native
0 Participants0 Participants
Race (NIH/OMB)
Phase 1
Asian
1 Participants1 Participants
Race (NIH/OMB)
Phase 1
Black or African American
10 Participants10 Participants
Race (NIH/OMB)
Phase 1
More than one race
0 Participants0 Participants
Race (NIH/OMB)
Phase 1
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants
Race (NIH/OMB)
Phase 1
Unknown or Not Reported
3 Participants3 Participants
Race (NIH/OMB)
Phase 1
White
57 Participants57 Participants
Race (NIH/OMB)
Phase 2
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Phase 2
Asian
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Phase 2
Black or African American
10 Participants2 Participants8 Participants
Race (NIH/OMB)
Phase 2
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Phase 2
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Phase 2
Unknown or Not Reported
3 Participants2 Participants1 Participants
Race (NIH/OMB)
Phase 2
White
52 Participants23 Participants29 Participants
Sex: Female, Male
Phase 1
Female
11 Participants11 Participants
Sex: Female, Male
Phase 1
Male
60 Participants60 Participants
Sex: Female, Male
Phase 2
Female
10 Participants3 Participants7 Participants
Sex: Female, Male
Phase 2
Male
56 Participants25 Participants31 Participants
Systolic Blood Pressure
Phase 1
133 mmHg
STANDARD_DEVIATION 15
133 mmHg
STANDARD_DEVIATION 15
Systolic Blood Pressure
Phase 2
134 mmHg
STANDARD_DEVIATION 15
136 mmHg
STANDARD_DEVIATION 14
132 mmHg
STANDARD_DEVIATION 16
Triglycerides
Phase 1
163 mg/dL
STANDARD_DEVIATION 107
163 mg/dL
STANDARD_DEVIATION 107
Triglycerides
Phase 2
157 mg/dL
STANDARD_DEVIATION 105
157 mg/dL
STANDARD_DEVIATION 54
157 mg/dL
STANDARD_DEVIATION 131
Waist Circumference
Phase 1
116 cm
STANDARD_DEVIATION 14
116 cm
STANDARD_DEVIATION 14
Waist Circumference
Phase 2
116 cm
STANDARD_DEVIATION 14
117 cm
STANDARD_DEVIATION 9
116 cm
STANDARD_DEVIATION 17

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 280 / 38
other
Total, other adverse events
0 / 280 / 38
serious
Total, serious adverse events
1 / 282 / 38

Outcome results

Primary

Carotid-femoral Pulse Wave Velocity

Phase 1 primary hypothesis: greater reduction in carotid-femoral pulse wave velocity with DASH diet in individuals with salt-sensitive blood pressure Change in velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness

Time frame: Phase 1 of study, change between week 2 and week 4

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsCarotid-femoral Pulse Wave Velocity-0.3 m/sStandard Deviation 1.6
Non Salt-sensitive ParticipantsCarotid-femoral Pulse Wave Velocity0.4 m/sStandard Deviation 3
p-value: 0.28Regression, Linear
Primary

Left Ventricular Mass Index

Left ventricular mass indexed to body surface area. Larger/greater left ventricular mass index is associated with increased long-term risk of cardiovascular events, including the development of heart failure. Normal values for men are 49-115 g/m² and for women 43-95 g/m²

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsLeft Ventricular Mass Index-3.3 g/m2Standard Deviation 15.5
Non Salt-sensitive ParticipantsLeft Ventricular Mass Index-1.7 g/m2Standard Deviation 12.2
p-value: 0.6Regression, Linear
Secondary

Carotid-femoral Pulse Wave Velocity

Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsCarotid-femoral Pulse Wave Velocity1.1 m/sStandard Deviation 1.5
Non Salt-sensitive ParticipantsCarotid-femoral Pulse Wave Velocity0.3 m/sStandard Deviation 1.9
p-value: 0.03Regression, Linear
Secondary

Global Longitudinal Left Ventricular Strain

Global longitudinal left ventricular strain (GLS), a sensitive measure of ventricular systolic function GLS is calculated by dividing the reduction in length of a myocardial (heart) segment from the end of diastole (maximum relaxation) to the end of systole (maximum contraction) by the segment's original length at end-diastole (i.e. change in length/original length). GLS is averaged across six myocardial segments, is expressed in a percentage, and is negative by convention since cardiac segment length decreases during systole. The more negative/greater magnitude, the better the GLS. Normal GLS is -18% to -22%. Low GLS is associated with long-term increased risk of cardiovascular events, including the development of heart failure.

Time frame: Phase 1 of study, change between week 2 to week 4

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsGlobal Longitudinal Left Ventricular Strain-0.2 ratioStandard Deviation 2.5
Non Salt-sensitive ParticipantsGlobal Longitudinal Left Ventricular Strain-0.5 ratioStandard Deviation 2
p-value: 0.27Regression, Linear
Other Pre-specified

24-hour Urinary Sodium Excretion

Measure of daily dietary sodium intake

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive Participants24-hour Urinary Sodium Excretion-456 mg/24hStandard Deviation 2077
Non Salt-sensitive Participants24-hour Urinary Sodium Excretion-204 mg/24hStandard Deviation 1721
Other Pre-specified

Clinic Diastolic Blood Pressure

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsClinic Diastolic Blood Pressure-3.2 mmHgStandard Deviation 10.7
Non Salt-sensitive ParticipantsClinic Diastolic Blood Pressure-3.5 mmHgStandard Deviation 10.8
p-value: 0.43generalized estimating equations
Other Pre-specified

Clinic Systolic Blood Pressure

Change in systolic blood pressure obtained in clinic with automated brachial cuff

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsClinic Systolic Blood Pressure-5.4 mmHgStandard Deviation 12.9
Non Salt-sensitive ParticipantsClinic Systolic Blood Pressure-4.1 mmHgStandard Deviation 15.8
p-value: 0.28generalized estimating equation
Other Pre-specified

Salt-sensitivity Phenotype

Salt-sensitive blood pressure means that blood pressure changes more than 'normal' when dietary sodium intake changes, i.e. increases or decreases in parallel with sodium intake. Having a salt-sensitive blood pressure pattern is an independent long-term risk factor for cardiovascular events. Variable testing approaches, blood pressure thresholds, and methods of blood pressure measurement have been proposed in the literature to define blood pressure salt-sensitivity. In this study, we report salt-sensitive vs. non salt-sensitive as a binary variable. Change in 24-hour mean blood pressure of \>= 4 mmHg between the ad-lib and home-delivered meal periods of Phase 1 defines the salt-sensitive blood pressure phenotype

Time frame: Phase 1 of study, change between week 2 and week 4

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Salt-sensitive ParticipantsSalt-sensitivity Phenotype9 Participants
Non Salt-sensitive ParticipantsSalt-sensitivity Phenotype22 Participants
Other Pre-specified

Sodium-restricted DASH Diet Adherence

Analysis of 3-day food diaries by a Registered Dietitian, utilizing the Nutrition Data System for Research. DASH diet adherence score based on proportion of recommended daily intake in 9 domains, score ranges 0-9 points with higher scores indicating greater adherence

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsSodium-restricted DASH Diet Adherence0.3 pointsStandard Deviation 1.3
Non Salt-sensitive ParticipantsSodium-restricted DASH Diet Adherence0.6 pointsStandard Deviation 1.6
p-value: 0.47generalized estimating equations
Other Pre-specified

Sodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ)

Sodium-restricted DASH diet score on FFQ, measured by quintiles of intake in 8 dietary domains as compared with age- and sex-matched norms from NHANES national US survey data. Score ranges 8-40 points, with higher scores indicating greater adherence

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsSodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ)1.5 pointsStandard Deviation 3.1
Non Salt-sensitive ParticipantsSodium-restricted DASH Diet Adherence by Food Frequency Questionnaire (FFQ)1.4 pointsStandard Deviation 2.8
Other Pre-specified

Triglycerides

Serum triglyceride changes during dietary intervention

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsTriglycerides41 mg/dLStandard Deviation 39
Non Salt-sensitive ParticipantsTriglycerides39 mg/dLStandard Deviation 127
p-value: 0.94t-test, 2 sided
Other Pre-specified

Urine Sodium and Potassium Ratios

Unitless ratio of urine sodium (in mmol) divided by urine potassium (in mmol), measured from spot samples taken from 24-hour urine samples.

Time frame: Phase 2 of study, change from baseline to 6 months

ArmMeasureValue (MEAN)Dispersion
Salt-sensitive ParticipantsUrine Sodium and Potassium Ratios-1.2 ratioStandard Deviation 1.1
Non Salt-sensitive ParticipantsUrine Sodium and Potassium Ratios-1.2 ratioStandard Deviation 1.2
p-value: 0.9t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026